This press release contains certain forward-looking statements about Efient for the reduction of thrombotic cardiovascular events (including stent thrombosis) in patients with acute coronary syndromes who are managed with percutaneous coronary intervention and reflects Daiichi Sankyo's and Lilly's current beliefs. However, as with any pharmaceutical product, there are substantial risks and uncertainties in the process of development and commercialization. There is no guarantee that future study results and patient experience will be consistent with study findings to date or that the product will be commercially successful. For further discussion of these and other risks and uncertainties, see Lilly's filing with the United States Securities and Exchange Commission and Daiichi Sankyo's filings with the Tokyo Stock Exchange. Daiichi Sankyo and Lilly undertake no duty to update forward-looking statements.
Efient(R) is a registered trademark of Eli Lilly and Company.
Plavix(R) is a registered trademark of Sanofi-Aventis Corp.
(1) Marzolini, C, et al, Polymorphisms in human MDR1 (P-gylcoprotein): Recent advances and clinical relevance. Clinical Pharmacology & Therapeutics, 2004;75(1):13-33.
(2) British Heart Foundation Health Promotion Research Group. European Cardiovascular Disease Statistics 2008 (http://www.ehnheart.org/files/statistics%202008%20web-161229...). Accessed 5 March 2010.
(3) American Heart Association. Heart Disease and Stroke Statistics - 2008 Update (http://www.americanheart.org/downloadabl...). Accessed 5 March 2010.
(4) WebMD Medical Reference in Collaboration with the Cleveland Clinic. Heart Disease: Coronary Artery Disease (http://www.webmd.com/heart-disease/guide/heart-disease-coron...). Accessed 5 March 2010.
(Logo: http://www.newscom.com/cgi-bin/prnh/20061120/DSLLOGO )
Derin Denham, Eli Lilly and Company, +1-317-277-6749 (office), +1-317-370-1435 (cell); Dr. Michaela Paudler-Debus, Daiichi Sankyo Europe GmbH, +49-(0)89-78-08-685 (office), +49-(0)172-845 8974 (cell); Shigemichi Kondo, Daiichi Sankyo (Tokyo), +81-3-6225-1126 (office)
